The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have raised questions about its promise. With only two gene therapies FDA-approved for rare diseases to date, the path to developing these medicines is still a difficult one.
This presentation exploreed how the biopharma industry can overcome development challenges in the pursuit of the promise of gene therapy.
